Articles by Ron Feemster - Pharmaceutical Executive

ADVERTISEMENT

Articles by Ron Feemster

Thought Leader: Q&A with Joel A. Tune

More Than a Safety Valve
Apr 1, 2006

The blockbuster era is at an end. Drugs are focused on smaller audiences today. With fewer doses to run, we must be flexible to support multiple molecules.

Lawsuit Alleges Pfizer Marketed Lipitor Too Broadly

Mar 29, 2006

A Q&A with Geoffrey Jarvis, counsel for the plaintiffs, with a response from Pfizer.

Holding Their Breath: Inhaled Insulin

Exubera, Pfizer's inhaled-insulin therapy, is carving out a new market for diabetes drugs. Four more companies are looking for their share.
Mar 1, 2006

All of the companies with inhaled-insulin drugs must perform two-year safety studies. Not because their drugs show troubling data, but because Exubera has caused slight, temporary decreases in lung function.

Gene Logic: Rescue Squad

One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets.
Feb 1, 2006

Pharma has an enormous backlog of drugs that never made it out of clinical trials. At Gene Logic, these discontinued drugs spell opportunity. Not only are they the foundation of a new business unit at Gene Logic, such failed compounds may become the cornerstone of a new approach to R&D as the industry confronts its latest productivity crisis.

The PharmExec 2005 Pipeline Report

Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and—at last—innovative mechanisms for troublesome targets.
Dec 1, 2005

Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and—at last—innovative mechanisms for troublesome targets.

Bad Rep? A Q&A with Jamie Reidy

Jamie Reidy wrote the book on how to slack off as a pharma sales rep. Now, the sales manager's nightmare unveils more scams, sizes up the corporate selling culture—and reveals what finally made him care.
Oct 1, 2005

TO HEAR JAMIE REIDY TELL IT, HE'S ALWAYS BEEN THE SORT of slacker who succeeds. He did enough work to get decent grades in high school and at Notre Dame University, which he attended on an ROTC scholarship.

ADVERTISEMENT

Click here